Abstract | BACKGROUND: METHODS: SAP levels in CSF and serum were determined in 30 controls, 67 MCI and 144 AD patients. At follow-up, 39 MCI patients had progressed to dementia, while 25 had remained stable (mean follow-up time: 2.6 +/- 1.0 and 2.1 +/- 0.8 years). RESULTS: Cross-sectionally no differences were found in SAP levels in CSF and serum between the groups. MCI patients that had progressed to dementia at follow-up had lower CSF SAP levels (13 microgram/l, range 3.3-199.3 microgram/l) than MCI nonprogressors (20.2 microgram/l, range 7.0-127.7 microgram/l; p < 0.05) [corrected]. A low CSF SAP level was associated with a 2-fold increased risk of progression to AD (hazard ratio = 2.2; 95% confidence interval = 0.9-5.4). CONCLUSION: Our data suggest that measurement of CSF SAP levels can aid in the identification of incipient AD among MCI patients.
|
Authors | Nicolaas A Verwey, Alie Schuitemaker, Wiesje M van der Flier, Sandra D Mulder, Cees Mulder, C Erik Hack, Philip Scheltens, Marinus A Blankenstein, Robert Veerhuis |
Journal | Dementia and geriatric cognitive disorders
(Dement Geriatr Cogn Disord)
Vol. 26
Issue 6
Pg. 522-7
( 2008)
ISSN: 1421-9824 [Electronic] Switzerland |
PMID | 19052452
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright 2008 S. Karger AG, Basel. |
Chemical References |
- Amyloid beta-Peptides
- Biomarkers
- Peptide Fragments
- Serum Amyloid P-Component
- amyloid beta-protein (1-42)
|
Topics |
- Aged
- Alzheimer Disease
(blood, cerebrospinal fluid)
- Amyloid beta-Peptides
(blood, cerebrospinal fluid)
- Biomarkers
- Cognition Disorders
(blood, cerebrospinal fluid)
- Cross-Sectional Studies
- Diagnosis, Differential
- Disease Progression
- Female
- Follow-Up Studies
- Humans
- Male
- Middle Aged
- Neuropsychological Tests
- Peptide Fragments
(blood, cerebrospinal fluid)
- Risk Factors
- Serum Amyloid P-Component
(cerebrospinal fluid, metabolism)
|